Enzo Life Sciences Exendin-4 GLP-1 receptor agonist
Exendin-4 is a 39 aa polypeptide and incretin mimetic which was first isolated from Gila monster saliva. The synthetic form, Exenatide, is a glucagon like peptide-1 (GLP-1) agonist approved for the treatment of diabetes mellitus type II.
Research shows Exendin-4 is involved in glucose-dependent enhancement of insulin secretion, reduction of hyperglycemia, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying and reduction of food intake, often with body weight reduction or blunting of weight gain.
Phone: 02 4575 0309
Biosynth carbohydrates
Within the carbohydrate product range, Biosynth offers tools for glycobiology, chemo-enzymatic...
Cayman Chemical Stem Cell Small Molecule Screening Library
The screening library contains more than 140 small molecules that are known either to induce...
Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)
Cayman Chemical's Bio-Active Lipid I Screening Library consists of 13 plates and contains...
Learn More
I am interested in Enzo Life Sciences Exendin-4 GLP-1 receptor agonist.
Complete the form and a supplier representative will be in touch.
